IM Cannabis (NASDAQ:IMCC) Posts Quarterly Earnings Results, Misses Estimates By $0.95 EPS

IM Cannabis (NASDAQ:IMCC) issued its quarterly earnings data on Monday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.95), Zacks reports. IM Cannabis had a negative return on equity of 134.35% and a negative net margin of 9.47%.

IM Cannabis Price Performance

Shares of IMCC opened at $0.41 on Tuesday. The company has a quick ratio of 0.56, a current ratio of 0.82 and a debt-to-equity ratio of 0.25. IM Cannabis has a twelve month low of $0.30 and a twelve month high of $7.12. The stock has a market capitalization of $2.40 million, a P/E ratio of -0.52 and a beta of 2.17. The company has a 50 day moving average of $0.94 and a 200-day moving average of $1.39.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in IM Cannabis stock. DRW Securities LLC bought a new stake in IM Cannabis Corp. (NASDAQ:IMCC) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 23,060 shares of the company’s stock, valued at approximately $32,000. DRW Securities LLC owned approximately 0.39% of IM Cannabis at the end of the most recent quarter. Institutional investors and hedge funds own 7.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IM Cannabis in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, IM Cannabis has a consensus rating of “Sell”.

About IM Cannabis

IM Cannabis Corp is a vertically integrated medical cannabis company based in Israel, specializing in the research, cultivation and production of cannabis-based formulations. The company holds three key licenses granted by the Israeli Ministry of Health, covering cultivation, possession and distribution of medical-grade cannabis. Its production facilities in Moshav Yizrael feature controlled-environment agriculture chambers designed to deliver consistent, high-purity cannabinoid profiles.

The company’s product portfolio includes standardized cannabis oils, distillates, vaporizer cartridges and topical preparations, all formulated under Good Manufacturing Practice (GMP) standards.